These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38529661)
1. Uracil- and Pyridine-Containing HDAC Inhibitors Displayed Cytotoxicity in Colorectal and Glioblastoma Cancer Stem Cells. Fiorentino F; Fabbrizi E; Raucci A; Noce B; Fioravanti R; Valente S; Paolini C; De Maria R; Steinkühler C; Gallinari P; Rotili D; Mai A ChemMedChem; 2024 Jul; 19(13):e202300655. PubMed ID: 38529661 [TBL] [Abstract][Full Text] [Related]
2. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179 [TBL] [Abstract][Full Text] [Related]
3. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents. Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876 [TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors. Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348 [TBL] [Abstract][Full Text] [Related]
7. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities. Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163 [TBL] [Abstract][Full Text] [Related]
9. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326 [TBL] [Abstract][Full Text] [Related]
10. Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids. Sodji QH; Kornacki JR; McDonald JF; Mrksich M; Oyelere AK Eur J Med Chem; 2015; 96():340-59. PubMed ID: 25899338 [TBL] [Abstract][Full Text] [Related]
11. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459 [TBL] [Abstract][Full Text] [Related]
12. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities. Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152 [TBL] [Abstract][Full Text] [Related]
13. Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. Rotili D; Tarantino D; Carafa V; Paolini C; Schemies J; Jung M; Botta G; Di Maro S; Novellino E; Steinkühler C; De Maria R; Gallinari P; Altucci L; Mai A J Med Chem; 2012 Sep; 55(18):8193-7. PubMed ID: 22931526 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Liu R; Wang J; Tang W; Fang H Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204 [TBL] [Abstract][Full Text] [Related]
15. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer. Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548 [TBL] [Abstract][Full Text] [Related]
16. Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. Mai A; Perrone A; Nebbioso A; Rotili D; Valente S; Tardugno M; Massa S; De Bellis F; Altucci L Bioorg Med Chem Lett; 2008 Apr; 18(8):2530-5. PubMed ID: 18381238 [TBL] [Abstract][Full Text] [Related]
17. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells. Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941 [TBL] [Abstract][Full Text] [Related]
18. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385 [TBL] [Abstract][Full Text] [Related]
19. Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation. Vu TK; Thanh NT; Minh NV; Linh NH; Thao NTP; Nguyen TTB; Hien DT; Chinh LV; Duc TH; Anh LD; Hai PT Med Chem; 2021; 17(7):732-749. PubMed ID: 32310052 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma. Umamaheswari A; Puratchikody A; Hari N Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]